Press Releases March 26, 2026 06:30 AM

BOSS Zhipin Repurchases 748,460 Shares; Total Repurchases Amount to Over RMB480 Million in 2026

KANZHUN LIMITED intensifies share repurchase program with over RMB480 million deployed in 2026

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED, trading as BOSS Zhipin on Nasdaq, announced ongoing execution of its share repurchase program, spending approximately RMB34.4 million to buy back 748,460 ordinary shares on March 25, bringing total repurchases in 2026 to over RMB480 million. This action reflects the company's commitment to enhance shareholder value.

BOSS Zhipin Repurchases 748,460 Shares; Total Repurchases Amount to Over RMB480 Million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED repurchased 748,460 shares using RMB34.4 million on March 25, 2026.
  • Total share repurchases in 2026 have surpassed RMB480 million.
  • The repurchase program signals strong commitment to shareholder returns and confidence in company valuation.

BEIJING, March 26, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB34.4 million to repurchase 748,460 ordinary shares on March 25. Year-to-date in 2026, the Company has deployed over RMB480 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Future share price volatility may affect the company's market capitalization and repurchase impact.
  • Large capital allocation to buybacks may limit funds available for operational growth or strategic investments.
  • Market conditions or regulatory changes could influence future repurchase activities or company performance.

More from Press Releases

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older Aug 13, 2026 Duolingo Invests in World-Class Motion Design with Acquisition of Animade Aug 13, 2026 Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update Aug 12, 2026 Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants Aug 12, 2026 Global Water Resources Reports Second Quarter 2026 Results Aug 12, 2026